2020’s

• 2025

  Additional NET (New Excellent Technology) certification acquired for FSD Fluor EX NHS ester Series
  ISO 9001 certification acquired (Quality Management System)
  Overseas distributor agreements signed with Labclinics (Spain, Portugal), 2BScientific (UK, Europe) and ASONE (USA)

• 2024

  ISO 13485 certification acquired (Medical Device Quality Management System)

• 2023

  In vitro diagnostic medical device manufacturing notification acquired from MFDS
  Portable MRSA in vitro diagnostic medical device registered with MFDS

• 2022

  BioActs USA Inc
  BALAMP M MRSA Detection Kit KGMP
  - BioActs USA Inc. (sales branch) established
  - BALAMP M MRSA (Methicillin-resistant Staphylococcus aureus) Detection Kit KGMP approved

• 2021

  - Acquired in vitro diagnostic medical device manufacturing license from Ministry of Food and Drug Safety Busan

• 2020

  CytoFlamma CBC Reagent GMP
  - Acquired medical device manufacturing license in March from Korea Food & Drug Administration and Korea conformity laboratories
  - Certified as a specialized company for material, parts and equipment in June by Korea Evaluation Institute of Industrial Technology
  - CytoFlamma CBC Reagent (whole blood analyzing reagents for flow cytometry) KGMP approved
  - Selected as an intellectual property business corporate

2010’s

• 2019

  Attracted the third round external capital funding.

• 2018

  Established MOU with Korea Atomic Energy Research Institute (KAERI)

• 2017

  Selected as INNOBIZ(innovative technology small company)
  Attracted the second round external capital funding.

• 2016

  Attracted the first round external capital funding.

• 2015

  Change company name to BioActs

• 2014

  Selected as a member of K-club of Korea Institute of Science and Technology.

• 2013

  인천비전기업 선정
  Selected as Incheon Visional Company

• 2012

  Recognized as a Visionary Company by Incheon Metropolitan city.
  Bioengineering, an affiliated institute of NIH.

• 2010

  Certified as an Advanced Technology Center (ATC) for biomolecular labeling materials.
  The New Excellent Technology (NET) certification acquired

2000’s

• 2009

  Biological business division (BioActs) established.

• 2005

  Antibacterial dyes and blue fluorescent OLED material production begin.

• 2002

  Ningbo Factory and Hangzhou Sales Corporation in China launched.

• 2001

  Awarded the presidential commendation and 5 million dollars export tower.

1990’s

• 1991

  Affiliated R&D center established; opened an era of innovative growth.

• 1976

  Corporation established; opened an era of creation and exploration.